| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
70,010,000 |
| Market
Cap: |
646.89(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.18 - $12.9 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Zymeworks is a clinical-stage biopharmaceutical company focused on the development of multifunctional biotherapeutics. Co.'s primary product candidate, zanidatamab, is a bispecific (dual-targeting) antibody that targets two domains of the human epidermal growth factor receptor 2. Co.'s second product candidate, ZW49, combines the design of zanidatamab with its ZymeLink antibody-drug conjugate platform, comprised of its proprietary cytotoxin (cancer cell-killing compound) and cleavable linker. Co. is also developing a pipeline of preclinical product candidates and discovery-stage programs in oncology (including immuno-oncology agents) and other therapeutic areas.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
2,475 |
| Total Sell Value |
$0 |
$0 |
$0 |
$20,045 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Priour James |
Chief Commercial Officer |
• – – |
2021-04-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,266 |
2,953 |
|
- |
|
| Odriscoll Kathryn |
Chief People Officer |
• – – |
2021-03-15 |
4 |
OE |
$34.24 |
$28,659 |
D/D |
837 |
5,840 |
|
- |
|
| Odriscoll Kathryn |
Chief People Officer |
• – – |
2021-03-15 |
4 |
S |
$34.72 |
$27,290 |
D/D |
(786) |
5,003 |
|
-4% |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2021-03-10 |
4 |
AS |
$34.95 |
$49,809 |
D/D |
(1,425) |
10,471 |
|
6% |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
11,896 |
|
- |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2021-03-10 |
4 |
AS |
$34.95 |
$36,631 |
D/D |
(1,048) |
30,979 |
|
6% |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
32,027 |
|
- |
|
| Odriscoll Kathryn |
Chief People Officer |
• – – |
2021-03-10 |
4 |
AS |
$34.95 |
$19,854 |
D/D |
(568) |
5,789 |
|
6% |
|
| Odriscoll Kathryn |
Chief People Officer |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,354 |
6,357 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2021-03-10 |
4 |
AS |
$34.95 |
$153,516 |
D/D |
(4,392) |
260,325 |
|
6% |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,708 |
264,717 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2021-03-10 |
4 |
AS |
$34.95 |
$36,631 |
D/D |
(1,048) |
5,377 |
|
6% |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2021-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
6,425 |
|
- |
|
| Odriscoll Kathryn |
Chief People Officer |
• – – |
2021-02-12 |
4 |
OE |
$34.24 |
$71,322 |
D/D |
2,083 |
5,003 |
|
- |
|
| Priour James |
Chief Commercial OfficerOffice |
• – – |
2021-01-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
687 |
|
-34% |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2021-01-08 |
4 |
A |
$30.92 |
$8,781 |
D/D |
284 |
9,406 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2021-01-08 |
4/A |
A |
$30.92 |
$8,781 |
D/D |
284 |
9,396 |
|
- |
|
| Polverino Anthony J. |
Chief Scientific Officer |
• – – |
2021-01-07 |
4 |
A |
$30.92 |
$1,484 |
D/D |
48 |
29,527 |
|
- |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2021-01-07 |
4 |
A |
$30.92 |
$6,400 |
D/D |
207 |
3,925 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2020-12-09 |
4/A |
S |
$53.25 |
$1,331,133 |
D/D |
(25,000) |
9,112 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2020-12-09 |
4/A |
OE |
$4.19 |
$129,399 |
D/D |
25,000 |
34,112 |
|
- |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2020-12-09 |
4 |
S |
$53.25 |
$1,331,133 |
D/D |
(25,000) |
9,122 |
|
48% |
|
| Klompas Neil A |
Chief Financial Officer |
• – – |
2020-12-09 |
4 |
OE |
$4.19 |
$129,399 |
D/D |
25,000 |
34,122 |
|
- |
|
| Tehrani Ali |
Chief Executive Officer |
• • – |
2020-12-07 |
4 |
S |
$56.16 |
$47,736 |
I/I |
(850) |
55,511 |
|
50% |
|
| Hausman Diane |
Chief Medical Officer |
• – – |
2020-12-04 |
4 |
AS |
$55.12 |
$332,476 |
D/D |
(6,032) |
3,718 |
|
-45% |
|
97 Records found
|
|
Page 2 of 4 |
|
|
0.43 (4.88%) 
